Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis

Alimentary Pharmacology & Therapeutics(2020)10.1111/apt.15935Source: DataRank Database

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis is a research paper published in Alimentary Pharmacology & Therapeutics (2020). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: hybridTopics (28)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Jonathan Velez Rivera,John R. Guyton ORCID,Mohammad Shadab Siddiqui ORCID,Arun J. Sanyal ORCID,Margery A. Connelly ORCID

Live enrichment

PubMed:32638417 PMC:PMC7497003

National Institutes of Health

Grant: R01 DK 105961

National Institutes of Health

Grant: 5R01DK105961-04

LIPIDOMICS BASED DIAGNOSTICS FOR NONALCOHOLIC STEATOHEPATITIS

hybridLicense: cc-by-nc

publisherhttps://doi.org/10.1111/apt.15935

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fapt.15935

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.15935

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7497003

Europe_PMChttps://europepmc.org/articles/PMC7497003

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

LiverHumansCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsLiver Function TestsRisk FactorsAtherosclerosisLipid MetabolismHypolipidemic AgentsNon-alcoholic Fatty Liver DiseaseDrug DevelopmentPioglitazone

Keywords

PioglitazoneAtherosclerosisLipid MetabolismDrug DevelopmentLiverLiver Function TestsCardiovascular DiseasesNon-alcoholic Fatty Liver DiseaseRisk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsReview ArticlesHypolipidemic Agents

Sustainable Development Goals

SDG 3: 3. Good health